Product
sabatolimab
2 clinical trials
5 indications
Indication
Myelodysplastic SyndromeIndication
Myelodysplastic SyndromesIndication
LeukemiaIndication
MyelomonocyticIndication
ChronicClinical trial
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R CriteriaStatus: Completed, Estimated PCD: 2023-05-08
Clinical trial
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Status: Recruiting, Estimated PCD: 2027-09-20